GLPBio

Apoptosis

Read More about this category

As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.

Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.

Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.

Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.

Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.

Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.

One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.

p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.

Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9). 

Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.

 

References:

1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.

2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.

3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.

4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.

5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.

Research Areas

Products Related to Apoptosis(3206)

  • GC79049 structure
    GC79049CG-1521
    CAS: 674767-29-4
    Purity: >95.50%

    CG-1521 is a histone deacetylase ( HDAC ) inhibitor that stabilizes Ac-Lys373 P53, increases P21 levels and HDAC2 degradation.

  • GC79050 structure
    GC79050OUL312
    Purity: >99.00%

    OUL312 is a potent PARP10 inhibitor ( IC 50 = 20 nM), showing more than 75-fold greater selectivity for PARP15 ( IC 50 = 1500 nM).

  • GC79057 structure
    GC79057BF-175
    CAS: 1333375-02-2
    Purity: >98.00%

    BF-175 is a selective SIRT1 agonist.

  • GC79058 structure
    GC79058PARP1/NAMPT-IN-1
    CAS: 3084810-86-3
    Purity: >98.00%

    PARP1/NAMPT-IN-1 is a potent and dual PARP1 and NAMPT inhibitor with IC 50 values of 1.2 nM and 6.7 nM, respectively.

  • GC79067 structure
    GC79067ADAR1i-124
    Purity: >98.50%

    ADAR1i-124 is an A-to-I RNA editing inhibitor by inhibiting the catalytic activities of both ADAR1p150 and ADAR1p110.

  • GC79070 structure
    GC79070WWQ-03-012
    CAS: 3076807-15-0
    Purity: >98.00%

    WWQ-03-012 is a selective DESI2 inhibitor with an IC 50 of 47.3 nM.

  • GC79072 structure
    GC79072MS6076
    Purity: >98.00%

    MS6076 is a mitochondrial protease ClpP agonist.

  • GC79077 structure
    GC79077DDO-6600
    CAS: 2640292-37-9
    Purity: >98.00%

    DDO-6600 is a covalent Hsp90 inhibitor.

  • GC79103 structure
    GC79103Berzosertib hydrochloride
    CAS: 1428935-04-9
    Purity: >98.50%

    Berzosertib (VE-822) hydrochloride is an orally active, CNS-penetrant, and selective ATR kinase inhibitor.

  • GC79104 structure
    GC79104(Rac)-Chem-0199
    CAS: 122981-77-5
    Purity: >99.50%

    (Rac)-Chem-0199 is the racemic mixture of Chem-0199.

  • GC79109 structure
    GC79109CZS-241 hydrochloride
    Purity: >98.50%

    CZS-241 hydrochloride is an orally active and selective inhibitor of Polo-like Kinase 4 ( PLK4 ) ( IC 50 =2.6 nM).

  • GC79111 structure
    GC79111CK2-TN03
    CAS: 313226-24-3
    Purity: >98.00%

    CK2-TN03 is an ATP-competitive casein kinase 2 ( CK2 ) inhibitor, with an IC 50 of 165 nM and a K i of 20 nM.

  • GC79118 structure
    GC79118Hydrangeic acid
    CAS: 491-79-2
    Purity: >96.00%

    Hydrangeic acid is an orally effective stilbene-type glycolipid metabolism regulator that lowers blood glucose and lipids.

  • GC79122 structure
    GC79122Opitor-0
    Purity: >98.00%

    Opitor-0 is a OPA1 GTPase inhibitor with an IC 50 of 3.0 μM.

  • GC79141 structure
    GC79141T7 Peptide TFA
    Purity: >98.00%

    T7 Peptide TFA is a protein synthesis inhibitor and anti-angiogenic agent, with a K d of 10 nM for human transferrin receptor.

  • GC79143 structure
    GC79143BRD4-IN-12
    CAS: 3112325-99-9
    Purity: >98.00%

    BRD4-IN-12 is a potent and orally active BRD4 inhibitor with an IC 50 of 7.9 nM.

  • GC79144 structure
    GC79144MC3817 free base
    Purity: >98.00%

    MC3817 free base is a selective DNMT1 inhibitor.

  • GC79145 structure
    GC79145MC3817
    Purity: >99.50%

    MC3817 is a selective DNMT1 inhibitor.

  • GC79146 structure
    GC79146Ischemin
    CAS: 1357059-00-7
    Purity: >99.50%

    Ischemin is a CBP bromodomain inhibitor that inhibits p53 interaction with CBP and transcriptional activity in cells.

  • GC79147 structure
    GC79147HLC40
    Purity: >99.50%

    HLC40 is a MLL1 histone methyltransferase inhibitor with an IC 50 of 0.82 μM by binding to WDR5.

  • GC79148 structure
    GC79148ZINC13000658
    CAS: 1324070-76-9
    Purity: >99.50%

    ZINC13000658 is a METTL inhibitor.

  • GC79149 structure
    GC79149WX2-43
    CAS: 723754-14-1
    Purity: >99.00%

    WX2-43 is a PRMT5-KLF4 inhibitor ( K d of 11.0 nM).

  • GC79194 structure
    GC79194Exendin-4-Cys
    Purity: >99.50%

    Exendin-4 -Cys is a cysteine-modified Exendin-4.

  • GC79195 structure
    GC79195Semaglutide-FITC
    Purity: >96.50%

    Semaglutide -FITC (Semaglutide-Lys(FITC)) is a fluorescent tracer probe (Ex/Em = 495/520 nm) obtained by covalently coupling the green fluorescent dye fluorescein isothiocyanate (FITC) to the long-acting analogue of GLP-1, Semaglutide.